10 reports

  • Telix Pharma Enters into Licensing Agreement with Wilex

PET/ MRI IS PRIMARILY USED IN FUNCTIONAL ASSESSMENT OF CANCER, ESPECIALLY CANCERS OF HEAD, NECK, BRAIN AND PROSTATE.

  • GE Healthcare Limited
  • Merck & Co., Inc.
  • Siemens AG
  • Terumo Corporation
  • WILEX AG
  • Telix Pharma Enters into Licensing Agreement with Wilex

PROSTATE CANCER IS THE SECOND LEADING CAUSE OF CANCER DEATH IN MEN.

  • GE Healthcare Limited
  • Merck & Co., Inc.
  • Siemens AG
  • Stryker Corporation
  • WILEX AG
  • Telix Pharma Enters into Licensing Agreement with Wilex

PET/ MRI IS PRIMARILY USED IN FUNCTIONAL ASSESSMENT OF CANCER, ESPECIALLY CANCERS OF HEAD, NECK, BRAIN AND PROSTATE.

  • GE Healthcare Limited
  • Merck & Co., Inc.
  • Siemens AG
  • Terumo Corporation
  • WILEX AG
  • Telix Pharma Enters into Licensing Agreement with Wilex

PET/ MRI IS PRIMARILY USED IN FUNCTIONAL ASSESSMENT OF CANCER, ESPECIALLY CANCERS OF HEAD, NECK, BRAIN AND PROSTATE.

  • Bruker Corporation
  • GE Healthcare Limited
  • Merck & Co., Inc.
  • Siemens AG
  • WILEX AG
  • TELIX PHARMA ENTERS INTO LICENSING AGREEMENT WITH WILEX

(EARLY DETECTION OF CERVICAL CANCER).

  • GE Healthcare Limited
  • Hitachi, Ltd.
  • Konica Minolta Group
  • Medtronic, Inc.
  • WILEX AG
  • Telix Pharma Enters into Licensing Agreement with Wilex

PET/ MRI IS PRIMARILY USED IN FUNCTIONAL ASSESSMENT OF CANCER, ESPECIALLY CANCERS OF HEAD, NECK, BRAIN AND PROSTATE.

  • GE Healthcare Limited
  • Merck & Co., Inc.
  • Siemens AG
  • Terumo Corporation
  • WILEX AG
  • Telix Pharma Enters into Licensing Agreement with Wilex

PET/ MRI IS PRIMARILY USED IN FUNCTIONAL ASSESSMENT OF CANCER, ESPECIALLY CANCERS OF HEAD, NECK, BRAIN AND PROSTATE.

  • GE Healthcare Limited
  • Merck & Co., Inc.
  • Siemens AG
  • Terumo Corporation
  • WILEX AG
  • Telix Pharma Enters into Licensing Agreement with Wilex

PET/ MRI IS PRIMARILY USED IN FUNCTIONAL ASSESSMENT OF CANCER, ESPECIALLY CANCERS OF HEAD, NECK, BRAIN AND PROSTATE.

  • GE Healthcare Limited
  • Merck & Co., Inc.
  • Siemens AG
  • Terumo Corporation
  • WILEX AG

Wilex Ag

90 99 77
  • Company Financials
  • WILEX AG
  • Target
  • MERGERS AND ACQUISITIONS - DEAL REPORTS

The assets belong to Oncogene Science, Inc., a research and development organization focused on cancer and oncogenes.

  • Pharmaceutical
  • United Kingdom
  • Company
  • Corporate Finance
  • WILEX AG